STRATA Skin Sciences(US:SSKN) Globenewswire·2025-05-19 12:00Core Viewpoint - STRATA Skin Sciences, Inc. has announced that the American Medical Association has accepted revisions to CPT codes 96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and autoimmune skin conditions beyond psoriasis, reflecting over 20 years of clinical evidence and real-world use of STRATA's XTRAC Excimer Lasers [1][2][3] Reimbursement Expansion - The updated CPT codes align with current FDA clearances and commercial payer coverage guidelines, expected to reduce systemic denials and the need for prior authorizations [2] - The revised codes explicitly include treatment for conditions such as vitiligo, atopic dermatitis, mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-cell lymphoma, potentially increasing the patient base from 10 million psoriasis patients to over 30 million [2][3] Clinical Significance - STRATA's CEO emphasized that this milestone reflects the broader clinical utility of the XTRAC excimer laser, supporting the mission to expand access to non-drug dermatologic solutions [3][5] - Experts in dermatology highlighted the importance of excimer lasers in transforming treatment for conditions like vitiligo and atopic dermatitis, validating the broader clinical value of the technology [3][4] Market Impact - The expanded CPT code coverage is expected to generate significant commercial growth, with non-psoriasis indications already accounting for approximately 30% of excimer laser treatment volume [3][6] - STRATA anticipates broader adoption of the XTRAC platform beyond the existing 1,400 clinics and 4,000 medical providers, supporting accelerated revenue growth under its recurring-use business model [3][6] Collaboration and Advocacy - STRATA has collaborated with leading clinical Key Opinion Leaders, patient advocacy groups, and the American Academy of Dermatology to advocate for the expanded indications of the XTRAC excimer laser [7]